170 related articles for article (PubMed ID: 36574171)
1. A comprehensive overview of AL amyloidosis disease characteristics accumulated over two decades at a single referral center in Korea.
Yoon SE; Kim D; Choi JO; Min JH; Kim BJ; Kim JS; Lee JE; Choi JY; Jeon ES; Kim SJ; Kim K
Int J Hematol; 2023 May; 117(5):706-717. PubMed ID: 36574171
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of autologous stem cell transplant for cardiac AL-amyloidosis and cardiac light chain deposition disease.
Abdallah AA; Alapat D; Kaur V; Atrash S
J Oncol Pharm Pract; 2020 Jul; 26(5):1128-1133. PubMed ID: 31795821
[TBL] [Abstract][Full Text] [Related]
3. Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UK.
Sharpley FA; Manwani R; Petrie A; Mahmood S; Sachchithanantham S; Lachmann HJ; Martinez De Azcona Naharro A; Gillmore JD; Whelan CJ; Fontana M; Cohen O; Hawkins PN; Wechalekar AD
Eur J Haematol; 2021 Apr; 106(4):537-545. PubMed ID: 33460466
[TBL] [Abstract][Full Text] [Related]
4. A real-life cohort study of immunoglobulin light-chain (AL) amyloidosis patients ineligible for autologous stem cell transplantation due to severe cardiac involvement or advanced disease.
Brunger AF; Nienhuis HLA; Bijzet J; Roeloffzen WWH; Vellenga E; Hazenberg BPC
Amyloid; 2020 Jun; 27(2):119-127. PubMed ID: 32052655
[No Abstract] [Full Text] [Related]
5. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
Jain T; Kosiorek HE; Kung ST; Shah VS; Dueck AC; Gonzalez-Calle V; Luft S; Reeder CB; Adams R; Noel P; Larsen JT; Mikhael J; Bergsagel L; Stewart AK; Fonseca R
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):486-492.e1. PubMed ID: 29753692
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea.
Kim SJ; Lee GY; Jang HR; Choi JO; Kim JS; Kim HJ; Lee SY; Min JH; Jeon ES; Kim K
Amyloid; 2013 Dec; 20(4):204-11. PubMed ID: 23914780
[TBL] [Abstract][Full Text] [Related]
7. The Role of Autologous Stem Cell Transplantation in Amyloidosis.
Vaxman I; Dispenzieri A
Oncology (Williston Park); 2021 Aug; 35(8):471-478. PubMed ID: 34398591
[TBL] [Abstract][Full Text] [Related]
8. Vincristine, Doxorubicin, and Dexamethasone Induction before Autologous Stem Cell Transplantation in Patients with AL Amyloidosis: A Retrospective Comparison with Frontline Stem Cell Transplantation.
Iijima T; Sawa N; Nakayama Y; Oba Y; Ikuma D; Mizuno H; Yamanouchi M; Suwabe T; Wake A; Kono K; Hoshino J; Ubara Y; Ohashi K
Intern Med; 2022 Oct; 61(19):2853-2860. PubMed ID: 35228429
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
10. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
[TBL] [Abstract][Full Text] [Related]
11. Cardiac and autologous stem cell transplantation hematopoietic in patients with AL amyloidosis.
Carretero M; Villanueva E; Brulc EB; Faelo FM; Aguirre MA; Pérez-de-Arenaza D; Belziti CA; Arbelbide JA; Nucifora EM; Posadas-Martinez ML
Arch Cardiol Mex; 2023; 93(4):435-441. PubMed ID: 37972368
[TBL] [Abstract][Full Text] [Related]
12. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
[TBL] [Abstract][Full Text] [Related]
13. Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy - A Single-Center Cohort Study of 227 Patients.
Feng J; Zhang C; Shen K; Sun J; Fang Q; Zhang L; Cao X; Zhou D; Li J; Tian Z
Circ J; 2019 Mar; 83(4):775-782. PubMed ID: 30773521
[TBL] [Abstract][Full Text] [Related]
14. Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis.
Abdallah N; Sidana S; Dispenzieri A; Lacy M; Buadi F; Hayman S; Kapoor P; Leung N; Dingli D; Hwa YL; Lust J; Russell S; Gonsalves W; Go R; Hogan W; Kyle R; Rajkumar SV; Gertz M; Kumar S
Bone Marrow Transplant; 2020 Jul; 55(7):1297-1304. PubMed ID: 32518290
[TBL] [Abstract][Full Text] [Related]
15. The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients.
Huang X; Ren G; Chen W; Guo J; Zhao L; Zeng C; Ge Y; Liu Z
Amyloid; 2021 Jun; 28(2):75-83. PubMed ID: 33084412
[TBL] [Abstract][Full Text] [Related]
16. [Autologous peripheral blood hematopoietic stem cell transplantation for patients with primary light chain amyloidosis: experience of 31 cases in a single center].
Li J; Feng J; Cao XX; Zhang CL; Shen KN; Huang XF; Zhang CL; Duan MH; Zhang W; Zhu TN; Cai HC; Zhang L; Cai H; Zhou DB
Zhonghua Xue Ye Xue Za Zhi; 2016 Mar; 37(3):201-4. PubMed ID: 27033756
[TBL] [Abstract][Full Text] [Related]
17. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation.
Leung N; Kumar SK; Glavey SV; Dispenzieri A; Lacy MQ; Buadi FK; Hayman SR; Dingli D; Kapoor P; Zeldenrust SR; Russell SJ; Lust JA; Hogan WJ; Rajkumar SV; Gastineau DA; Kourelis TV; Lin Y; Gonsalves WI; Go RS; Gertz MA
Nephrol Dial Transplant; 2016 Aug; 31(8):1284-9. PubMed ID: 26627634
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation.
Al Saleh AS; Sidiqi MH; Muchtar E; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1402-1405. PubMed ID: 32422250
[TBL] [Abstract][Full Text] [Related]
19. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of Engraftment Syndrome following Autologous Stem Cell Transplantation in Light Chain Amyloidosis with Renal Involvement.
Miao F; Ren G; Guo J; Zhao L; Xu W; Huang X
Transplant Cell Ther; 2023 Feb; 29(2):110.e1-110.e8. PubMed ID: 36323398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
